Home >> Pharmaceuticals >> Food & Beverage >>

Opexa Therapeutics, Inc. - Product Pipeline Review - 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 24 | Code: MRS - 35169

Opexa Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Opexa Therapeutics, Inc. - Product Pipeline Review - 2015’, provides an overview of the Opexa Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Opexa Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Opexa Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Opexa Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Opexa Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Opexa Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Opexa Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Opexa Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Opexa Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Opexa Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Opexa Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Opexa Therapeutics, Inc. Snapshot 4
Opexa Therapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
Opexa Therapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Opexa Therapeutics, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Opexa Therapeutics, Inc. - Pipeline Products Glance 9
Opexa Therapeutics, Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Opexa Therapeutics, Inc. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Opexa Therapeutics, Inc. - Drug Profiles 11
imilecleucel-t 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
OPX-212 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Stem Cell Therapy for Type 1 Diabetes 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Opexa Therapeutics, Inc. - Pipeline Analysis 15
Opexa Therapeutics, Inc. - Pipeline Products by Target 15
Opexa Therapeutics, Inc. - Pipeline Products by Route of Administration 16
Opexa Therapeutics, Inc. - Pipeline Products by Molecule Type 17
Opexa Therapeutics, Inc. - Pipeline Products by Mechanism of Action 18
Opexa Therapeutics, Inc. - Recent Pipeline Updates 19
Opexa Therapeutics, Inc. - Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 23
Disclaimer 24

List of Tables
Opexa Therapeutics, Inc., Key Information 4
Opexa Therapeutics, Inc., Key Facts 4
Opexa Therapeutics, Inc. - Pipeline by Indication, 2015 6
Opexa Therapeutics, Inc. - Pipeline by Stage of Development, 2015 7
Opexa Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 8
Opexa Therapeutics, Inc. - Phase II, 2015 9
Opexa Therapeutics, Inc. - Preclinical, 2015 10
Opexa Therapeutics, Inc. - Pipeline by Target, 2015 15
Opexa Therapeutics, Inc. - Pipeline by Route of Administration, 2015 16
Opexa Therapeutics, Inc. - Pipeline by Molecule Type, 2015 17
Opexa Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 18
Opexa Therapeutics, Inc. - Recent Pipeline Updates, 2015 19

List of Figures
Opexa Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015 6
Opexa Therapeutics, Inc. - Pipeline by Stage of Development, 2015 7
Opexa Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 8
Opexa Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015 16
Opexa Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015 17

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing